ERBB2 and breast cancer: The highest mutational frequency for all of the genes assessed in this study (PIK3CA and/or PIK3R1 and/or AKT1) was observed in HR+/ERBB2- tumors (133/289; 46.0%), while mutations were observed in up to 28% of cases in other breast cancer subtypes.